The Experts below are selected from a list of 9744 Experts worldwide ranked by ideXlab platform
Jai Chitnavis - One of the best experts on this subject based on the ideXlab platform.
-
total knee arthroplasty in a Patient with hemophilic arthropathy and high titer inhibitors a cost analysis
Journal of Arthroplasty, 2012Co-Authors: Alan J Howieson, Kingsley Lawrence, Dipti Chitnavis, Jai ChitnavisAbstract:Abstract A Patient with Hemophilia A, who developed factor VIII inhibitors and initially had funding for his total knee arthroplasty declined, is discussed. A total of £1 542 000 (US $2 474 603) was spent on medical treatment for recurrent hemarthroses over a 4-year period, while funding was sought. In comparison, the total cost for his knee arthroplasty was £542 858 (US $871 084) including perioperative recombinant clotting factors. Postoperatively, with 1-year follow-up, no further hemoarthroses have occurred; his analgesic requirement is significantly reduced; he has a much improved level of function; and treatment costs are significantly reduced, leading to a substantial overall saving. Our findings suggest that surgical treatment is beneficial and cost-effective for Patients with Hemophilia with inhibitors. Hospitals should not deny operative treatment based on cost alone.
Francisco Veas - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of trypanosoma cruzi encephalitis in a Patient with Hemophilia and aids
Clinical Infectious Diseases, 1993Co-Authors: Aldo Solari, Hernan Saavedra, Cecilia Sepulveda, D Oddo, G Acuna, Jaime Labarca, Sergio Munoz, Gerard Cuny, Cecille Brengues, Francisco VeasAbstract:Although the frequency of infection with the human immunodeficiency virus (HIV) is increasing dramatically in areas where Trypanosoma cruzi is endemic, trypanosomiasis has been rarely reported in persons with HIV infection or AIDS. Persons with Hemophilia who receive multiple blood product transfusions from blood banks with little or no screening for infectious agents are at particularly high risk for infections with both HIV and T. cruzi. We describe the case of a person with Hemophilia who was infected by blood transfusion with HIV and T. cruzi and in whom a multifocal, necrotic trypanosomal encephalitis was demonstrated by brain biopsy and electron microscopy. Treatment with benznidazole followed by that with itraconazole and fluconazole was associated with significant clinical and radiographic improvement.
Alan J Howieson - One of the best experts on this subject based on the ideXlab platform.
-
total knee arthroplasty in a Patient with hemophilic arthropathy and high titer inhibitors a cost analysis
Journal of Arthroplasty, 2012Co-Authors: Alan J Howieson, Kingsley Lawrence, Dipti Chitnavis, Jai ChitnavisAbstract:Abstract A Patient with Hemophilia A, who developed factor VIII inhibitors and initially had funding for his total knee arthroplasty declined, is discussed. A total of £1 542 000 (US $2 474 603) was spent on medical treatment for recurrent hemarthroses over a 4-year period, while funding was sought. In comparison, the total cost for his knee arthroplasty was £542 858 (US $871 084) including perioperative recombinant clotting factors. Postoperatively, with 1-year follow-up, no further hemoarthroses have occurred; his analgesic requirement is significantly reduced; he has a much improved level of function; and treatment costs are significantly reduced, leading to a substantial overall saving. Our findings suggest that surgical treatment is beneficial and cost-effective for Patients with Hemophilia with inhibitors. Hospitals should not deny operative treatment based on cost alone.
Raymond G Watts - One of the best experts on this subject based on the ideXlab platform.
-
successful use of recombinant factor viia for emergency fasciotomy in a Patient with Hemophilia a and high titer inhibitor unresponsive to factor viii inhibitor bypassing activity
American Journal of Hematology, 2005Co-Authors: Raymond G WattsAbstract:We report a Patient with Hemophilia A and high-titer factor VIII inhibitor who developed compartment syndrome of his forearm following trauma. Emergency fasciotomy was performed. Initial hemostatic treatment with factor VIII inhibitor bypassing activity (FEIBA) was unsuccessful. Bleeding was controlled with recombinant factor VIIa.
Miguel A Escobar - One of the best experts on this subject based on the ideXlab platform.
-
thrombelastography guided factor viia therapy in a surgical Patient with severe Hemophilia and factor viii inhibitor
Anesthesia & Analgesia, 2008Co-Authors: Evan G Pivalizza, Miguel A EscobarAbstract:A Patient with Hemophilia and factor VIII inhibitors required urgent evacuation of a spinal cord hematoma. Two large doses of recombinant factor VIIa (200 microg/kg followed by 300 microg/kg) were required for hemostasis. Traditional and rotational thrombelastography were used to guide dose and timing of rFVIIa therapy. with the limitations of prothrombin and partial thromboplastin times as perioperative monitors of rFVIIa efficacy, this description of thrombelastography supports reports of in vitro use, and may be helpful when large perioperative doses of rFVIIa are required.